Emicizumab (marketed name Hemlibra®®) is a BsAb that was developed to treat hemophilia A. The BsAb binds to coagulation Factors X and IX and is therefore able to play the role of Factor XIII—the coagulation factor missing in many hemophilia A patients [61,62]. This evidence concerns the gene F10 and hemophilia A.